Eupraxia Pharmaceuticals Inc.
EPRXHealthcareNASDAQBiotechnology · Last scanned Jun 2, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Eupraxia Pharmaceuticals Inc. focuses on Biotechnology services and products. Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The $434.4M market capitalization puts EPRX squarely in small-cap range for its industry. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
Market Cap
$434.4M
Beta
1.42
P/E (TTM)
—
P/E (Fwd)
-7.19
EPS (TTM)
$-1.05
EPS (Fwd)
$-0.92
ROE
-54.5%
ROA
-33.8%
Cash
$138.9M
Total Debt
$2.0M
Free CF
-$17.6M
52W Change
67.5%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $138.9M in cash comfortably exceeding the $2.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$17.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -54.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Eupraxia Pharmaceuticals Inc.'s trajectory.